av-412
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00381654)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
EGFR inhibitor
ERBB2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cc(C#CC(C)(C)N2CCN(C)CC2)cc2ncnc(Nc3ccc(F)c(Cl)c3)c12.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1- Mol. weight
- 851.42 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6067986 ↗
- ChEMBLCHEMBL5095492 ↗
- ChEMBLCHEMBL5095024 ↗
- ChEMBLCHEMBL3545002 ↗
Also known as
- av 412
- av-412
- av-412
- av-412
- av-412
- av412 cpd
- mp 412
- mp-412
- mp-412
- mp-412
- mp412 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00551850 | Phase 1 | Oct 1, 2007 | AVEO Pharmaceuticals |
| NCT00381654 | Phase 1 | Oct 1, 2006 | AVEO Pharmaceuticals, Centro Integral Oncológica Clara Campal, Hospital Universitario Austral, Johns Hopkins University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AVEO Pharmaceuticals | For profit | 2 | 2 | 1 | 2006 |
| Centro Integral Oncológica Clara Campal | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Hospital Universitario Austral | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1